Acute Lymphoblastic Leukemia (ALL) is a rapidly progressing cancer of the blood and bone marrow that primarily affects lymphoid lineages, predominantly impacting children, though adults are also increasingly diagnosed. The therapeutic landscape for ALL has evolved significantly over the past decades, driven by advancements in molecular biology, targeted therapies, and immunotherapies.... https://www.coherentmarketinsights.com/market-insight/acute-lymphoblastic-leukemia-therapeutics-market-1606